Surgery versus radiation therapy for patients with
aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles.
Aggressive fibromatosis. Am J Clin Oncol 2005;28:211-5.
Verhoef, "Time trends in the incidence and treatment of extra-abdominal and abdominal
aggressive fibromatosis: a population-based study," Annals of Surgical Oncology, vol.
He, "Clinical management of pediatric
aggressive fibromatosis involving the mandible," Pediatr Blood and Cancer, vol.
Khan, "Successful management of
aggressive fibromatosis of the neck using wide surgical excision: a case report," Journal of Medical Case Reports, vol.
Demetri et al., "Clinical and molecular studies of the effect of imatinib on advanced
aggressive fibromatosis (desmoid tumor)," Journal of Clinical Oncology, vol.
Aggressive fibromatosis (AF) or extra-abdominal desmoid tumours are rare tumours of fibroblastic origin involving the proliferation of cytologically benign fibrocytes.1 AF accounts for about 0.03% of all neoplasms and >3% of all soft tissue tumours with a reported incidence of 2 to 4 cases per million population per year.2 The characteristic features of AF are slow growth, benign but locally aggressive behaviour and high recurrence rate without metastasising capacity.
Tests found an
aggressive fibromatosis, a soft-tissue cancerous growth that affects no more than four people in a million.
Desmoid tumour, also known as
aggressive fibromatosis, is the primary differential diagnosis.
Metastatic lesions (Figure 7) and benign processes, such as
aggressive fibromatosis (desmoid tumor), endometriosis or nodular fasciitis, may also involve the plexus.
Desmoid-type fibromatosis [1], also known as "deep fibromatosis" or "
aggressive fibromatosis," is a relatively rare mesenchymal neoplasm which arises from a proliferation of bland-looking fibroblasts and myofibroblasts.